Pyrosequencing AB, a subsidiary of Biotage AB, Uppsala, Sweden, has announced the launch of PyroMark(TM)Q24 the latest in the range of Pyrosequencing(R) Systems. This new high-performance platform includes a complete software package for the study of genetic and epigenetic variation of genes, providing CpG methylation allele quantification and mutation analysis. These studies are used for a wide range of clinical research, for example the identification and tracking of changes involved in various forms of cancer. Studying these changes using Pyrosequencing(R) technology, which is based on the principals of sequencing by synthesis, is an ideal choice for genetic analysis in ...